$0.02 EPS Expected for Absolute Software (ALSWF); 5 Analysts Bullish Aclaris Therapeutics, Inc. (ACRS)

April 18, 2018 - By Hazel Jackson

Absolute Software Corporation (OTCMKTS:ALSWF) Logo

Analysts expect Absolute Software Corporation (OTCMKTS:ALSWF) to report $0.02 EPS on May, 14.They anticipate $0.03 EPS change or 300.00% from last quarter’s $-0.01 EPS. ALSWF’s profit would be $773,715 giving it 65.88 P/E if the $0.02 EPS is correct. After having $-0.01 EPS previously, Absolute Software Corporation’s analysts see -300.00% EPS growth. The stock decreased 1.86% or $0.1 during the last trading session, reaching $5.27. About 1,500 shares traded. Absolute Software Corporation (OTCMKTS:ALSWF) has 0.00% since April 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 6 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aclaris Therapeutics had 14 analyst reports since November 2, 2015 according to SRatingsIntel. Jefferies maintained Aclaris Therapeutics, Inc. (NASDAQ:ACRS) rating on Monday, September 19. Jefferies has “Buy” rating and $31 target. The firm has “Market Perform” rating given on Friday, September 30 by JMP Securities. The firm earned “Buy” rating on Monday, November 2 by Citigroup. The firm has “Buy” rating by Jefferies given on Friday, August 12. The rating was initiated by Guggenheim on Friday, June 10 with “Buy”. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, November 7. As per Monday, June 26, the company rating was maintained by Jefferies. Leerink Swann initiated the stock with “Outperform” rating in Tuesday, November 29 report. Jefferies maintained the stock with “Buy” rating in Friday, July 28 report. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) earned “Buy” rating by Jefferies on Monday, November 2. See Aclaris Therapeutics, Inc. (NASDAQ:ACRS) latest ratings:

07/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $50.0 Maintain

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. The company has market cap of $540.78 million. The Company’s lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis , a common non-malignant skin tumor. It currently has negative earnings. The firm is also developing A-101 as a prescription treatment for common warts.

The stock decreased 4.00% or $0.73 during the last trading session, reaching $17.5. About 208,415 shares traded. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has declined 45.27% since April 18, 2017 and is downtrending. It has underperformed by 56.82% the S&P500.

Absolute Software Corporation develops, markets, and supports endpoint security and data risk management, and endpoint management solutions for desktops, laptops, tablets, and smartphones in Canada, the United States, and internationally. The company has market cap of $203.87 million. The firm operates through two divisions, Data and Device Security, and Endpoint and Service Management. It currently has negative earnings. The Company’s software-as-a-service solutions enable clients to secure endpoints, assess risk, and respond to security threats.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.